AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25224929 — intervention group
Group type: EXPERIMENTAL
Intervention: IM twice/day (α1-blocker + 0.1 mg imidafenacin twice daily)
Number of subjects: 0
Study 25224929 — intervention group
Group type: EXPERIMENTAL
Intervention: IM nightly (α1-blocker + 0.1 mg imidafenacin nightly)
Number of subjects: 0
Study 25224929 — intervention group
Group type: COMPARATOR
Intervention: Control (α1-blocker alone)
Number of subjects: 0
Study 24574836 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB Gold (QFT-Gold) test
Number of subjects: 143
Study 24574836 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 143
Study 24574836 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative TST results in RA patients
Number of subjects: 143
Study 22837306 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRP-3
Number of subjects: 345
Study 22837306 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDF
Number of subjects: 345
Study 22837306 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRP-3 and PEDF
Number of subjects: 345
Study 19926098 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine treatment
Number of subjects: 2006
Study 19926098 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine treatment started early
Number of subjects: 2006
Study 19926098 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine treatment started late
Number of subjects: 2006
Study 17707720 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 5 mg administered orally before ovulation (Group A)
Number of subjects: 15
Study 17707720 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 5 mg administered orally after ovulation (Group B)
Number of subjects: 15
Study 17707720 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 5 mg administered (both groups)
Number of subjects: 15
Study 16075231 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous patellar bone‐tendon‐bone (BTB) grafts
Number of subjects: 79
Study 16075231 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon (ST) grafts
Number of subjects: 79
Study 12625150 — intervention group
Group type: EXPERIMENTAL
Intervention: tafenoquine (3‐d)
Number of subjects: 586
Study 12625150 — intervention group
Group type: COMPARATOR
Intervention: primaquine (14‐d)
Number of subjects: 586
Study 9865208 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy photon therapy (LEPT)
Number of subjects: 9
Study 9865208 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 9
Study 8560536 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inactivated whole cell plus recombinant B subunit (WC/rBS) cholera vaccine, 2 doses, 2 weeks apart
Number of subjects: 346
Study 8560536 — intervention group
Group type: COMPARATOR
Intervention: Escherichia coli K12 placebo, 2 doses, 2 weeks apart
Number of subjects: 346
Study 8560536 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inactivated whole cell plus recombinant B subunit (WC/rBS) cholera vaccine
Number of subjects: 346
Study 8560536 — intervention group
Group type: COMPARATOR
Intervention: Escherichia coli K12 placebo
Number of subjects: 346
Study 2482650 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486, 25 mg twice daily for 4 days (Group I)
Number of subjects: 40
Study 2482650 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486, 25 mg for 3 days (Group II)
Number of subjects: 40
Study 2482650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of sulprostone, 0.25 mg on the last day of RU 486 treatment
Number of subjects: 40
Study 2482650 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma beta‐hCG and progesterone levels
Number of subjects: 40
Study 2482650 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cortisol levels
Number of subjects: 40
Study 7209671 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion with instrumentation
Number of subjects: 63
Study 7209671 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy with fusion and instrumentation
Number of subjects: 63
Study 7209671 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy alone
Number of subjects: 63
Study 7209671 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy with fusion without instrumentation
Number of subjects: 63
Study 7209671 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion alone
Number of subjects: 63
Study 7209671 — intervention group
Group type: COMPARATOR
Intervention: No operation
Number of subjects: 63
Study 7209671 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed rehabilitation program
Number of subjects: 63
Study 31367979 — intervention group
Group type: EXPERIMENTAL
Intervention: EX‐PRESS glaucoma filtration device implantation
Number of subjects: 32
Study 28733855 — intervention group
Group type: COMPARATOR
Intervention: Professional Development provided by trained Ugandan mental health professionals to Ugandan primary school teachers; included large‐group experiential training and small‐group coaching; duration of 4-5 months.
Number of subjects: 79
Study 28733855 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition; no specific intervention details provided.
Number of subjects: 79
Study 26446696 — intervention group
Group type: EXPERIMENTAL
Intervention: Single training of GPs in the pharmacological management of HF drug therapy according to ESC guidelines
Number of subjects: 30
Study 26446696 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 30
Study 23414504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine cholera toxin B conjugate vaccine
Number of subjects: 55
Study 21550906 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 6789
Study 21550906 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 6789
Study 19735396 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainees
Number of subjects: 32
Study 19735396 — intervention group
Group type: EXPERIMENTAL
Intervention: Experts
Number of subjects: 32
Study 19635069 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-site CRT-D
Number of subjects: 100
Study 19635069 — intervention group
Group type: COMPARATOR
Intervention: Standard CRT-D
Number of subjects: 100
Study 15281472 — intervention group
Group type: EXPERIMENTAL
Intervention: Butterbur, 50 mg twice daily
Number of subjects: 35
Study 15281472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15460761 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based randomisation service
Number of subjects: 0
Study 9121678 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (n = 8) used emotional strategies (positive emotions for left hemisphere activation, negative emotion for right hemisphere activation)
Number of subjects: 16
Study 9121678 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (n = 8) received no guidance
Number of subjects: 16
Study 8214745 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate (1.5 mg/kg)
Number of subjects: 16
Study 8214745 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 16
Study 2447715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran Group
Number of subjects: 275
Study 2447715 — intervention group
Group type: COMPARATOR
Intervention: Plasma Group
Number of subjects: 275
Study 11590533 — intervention group
Group type: EXPERIMENTAL
Intervention: GW420867X 50 mg/day
Number of subjects: 60
Study 11590533 — intervention group
Group type: EXPERIMENTAL
Intervention: GW420867X 100 mg/day
Number of subjects: 60
Study 11590533 — intervention group
Group type: EXPERIMENTAL
Intervention: GW420867X 200 mg/day
Number of subjects: 60
Study 11590533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (GW420867X, 3TC, and ZDV placebos)
Number of subjects: 60
Study 11590533 — intervention group
Group type: EXPERIMENTAL
Intervention: GW420867X (all doses combined)
Number of subjects: 60
Study 29948224 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid collection bags
Number of subjects: 43
Study 29948224 — intervention group
Group type: COMPARATOR
Intervention: Negative control samples (intracapsular tissue samples)
Number of subjects: 43
Study 26761379 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (S group)
Number of subjects: 50
Study 26761379 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid block (C group)
Number of subjects: 50
Study 24967813 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal 25‐OHD deficiency (<37.5 nmol/L)
Number of subjects: 960
Study 24967813 — intervention group
Group type: EXPERIMENTAL
Intervention: For every 25 nmol increase in 25‐OHD concentration in late pregnancy
Number of subjects: 960
Study 22579034 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning group with access to the ECOFISIO website
Number of subjects: 46
Study 22579034 — intervention group
Group type: COMPARATOR
Intervention: Control group with access to documents and books
Number of subjects: 46
Study 22579034 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning group
Number of subjects: 46
Study 20627974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=127) attended four interactive group sessions and received monthly support via text messages for 12 months
Number of subjects: 250
Study 20627974 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=123) attended one non‐interactive information session
Number of subjects: 250
Study 20627974 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference in weight change between intervention and control groups
Number of subjects: 250
Study 20627974 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analysis for total cholesterol concentration
Number of subjects: 250
Study 20627974 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analysis for self management behaviours (diet score)
Number of subjects: 250
Study 20627974 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analysis for self management behaviours (physical activity score)
Number of subjects: 250
Study 20627974 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analysis for confidence to control weight
Number of subjects: 250
Study 20627974 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular self weighing in the intervention group
Number of subjects: 250
Study 18662191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (45 mg/h for 3 hours followed by 90 mg/h for 5 hours)
Number of subjects: 5
Study 15744450 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium mineral water (HCaMW) - 1 liter daily (596 mg Ca/l)
Number of subjects: 180
Study 15744450 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 1 liter of mineral water with low calcium content (10 mg/l)
Number of subjects: 180
Study 15744450 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium mineral water (HCaMW) with vitamin D (400 iu/day)
Number of subjects: 180
Study 11796428 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone for 3 months followed by inhaled budesonide for 15 months (800 microg bid)
Number of subjects: 189
Study 11796428 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets followed by placebo inhaler therapy
Number of subjects: 189
Study 10732870 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU 120 mg/m2 d.l, VP 16 60 mg/in2 d.2‐4, procarbazine 85 mg/m2 d. 2‐8 (Arm A)
Number of subjects: 47
Study 10732870 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 6 mg/m2 d.l with VP16 and procarbazine in the same dosage and schedule (Arm B)
Number of subjects: 47
Study 10732870 — intervention group
Group type: COMPARATOR
Intervention: Both arms pooled results
Number of subjects: 47
Study 10732870 — intervention group
Group type: COMPARATOR
Intervention: Initial performance status
Number of subjects: 47
Study 10732870 — intervention group
Group type: COMPARATOR
Intervention: Presence of significant antecedent and/or concomitant disease (SACD)
Number of subjects: 47
Study 7745507 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 446
Study 7745507 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 446
Study 7745507 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant and Air placebo
Number of subjects: 446
Study 2029015 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour esophageal pH monitoring
Number of subjects: 100
Study 2029015 — intervention group
Group type: COMPARATOR
Intervention: Esophageal manometry
Number of subjects: 100
Study 2029015 — intervention group
Group type: COMPARATOR
Intervention: Acid perfusion test
Number of subjects: 100
Study 2029015 — intervention group
Group type: COMPARATOR
Intervention: Edrophonium test
Number of subjects: 100
Study 6941445 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of tinidazole administered 8-15 hours before the abortion
Number of subjects: 212
Study 6941445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 31321428 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast of oats and milk (431 kcal; 65 g carbohydrate, 11 g fat, 19 g protein) followed by rest (BR)
Number of subjects: 12
Study 31321428 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast before exercise (BE; 60 min cycling at 50 % peak power output)
Number of subjects: 12
Study 31321428 — intervention group
Group type: COMPARATOR
Intervention: Overnight fasting before exercise (FE)
Number of subjects: 12
Study 29241508 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based intervention using multiple languages
Number of subjects: 0
Study 25580775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone (0.5mg)
Number of subjects: 253
Study 25580775 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (15mg)
Number of subjects: 253
Study 24304626 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology therapy for 30 minutes on feet, hands, and ears for 5 days
Number of subjects: 60
Study 24304626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reflexology therapy)
Number of subjects: 60
Study 24304626 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology therapy
Number of subjects: 60
Study 21861639 — intervention group
Group type: EXPERIMENTAL
Intervention: MGCSH mixed with PRP
Number of subjects: 16
Study 21861639 — intervention group
Group type: COMPARATOR
Intervention: Collagen resorbable plug
Number of subjects: 16
Study 21861639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 19609242 — intervention group
Group type: EXPERIMENTAL
Intervention: protamine-protected mRNA vaccination with KLH
Number of subjects: 21
Study 19609242 — intervention group
Group type: EXPERIMENTAL
Intervention: protamine-protected mRNA vaccination without KLH
Number of subjects: 21
Study 19609242 — intervention group
Group type: EXPERIMENTAL
Intervention: protamine-protected mRNA vaccination
Number of subjects: 21
Study 17464992 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevudine 30 mg once daily for 24 weeks
Number of subjects: 243
Study 17464992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 16236838 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (Turbuhaler), 24 microg bid for 4 weeks
Number of subjects: 15
Study 16236838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16236838 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Turbuhaler), 400 microg bid for 4 weeks (gold standard comparison)
Number of subjects: 15
Study 11296078 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketorolac (0.5 to 1 mg/kg) and IV fluids
Number of subjects: 51
Study 9693699 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 67
Study 9693699 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' report
Number of subjects: 67
Study 7841087 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 7841087 — intervention group
Group type: COMPARATOR
Intervention: Control (no verapamil)
Number of subjects: 0
Study 3419942 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory teaching method using anatomic dolls
Number of subjects: 159
Study 3419942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐perceptual teaching method using two-dimensional drawings
Number of subjects: 159
Study 3419942 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study 31063421 — intervention group
Group type: EXPERIMENTAL
Intervention: ULRI‐IE/IT
Number of subjects: 23
Study 31063421 — intervention group
Group type: COMPARATOR
Intervention: Unassisted fluoroscopy
Number of subjects: 23
Study 29206631 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine beclomethasone (HFA-QVAR)
Number of subjects: 43
Study 29206631 — intervention group
Group type: COMPARATOR
Intervention: Non-extrafine beclomethasone (HFA-Clenil)
Number of subjects: 43
Study 29206631 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone (HFA-Flixotide)
Number of subjects: 43
Study 25735565 — intervention group
Group type: EXPERIMENTAL
Intervention: Socket augmentation
Number of subjects: 38
Study 25735565 — intervention group
Group type: COMPARATOR
Intervention: Non-augmented sockets
Number of subjects: 38
Study 24161288 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: MP (2 mg/kg) after lidocaine (0.6 mg/kg) with a tourniquet with arm down (venous engorgement)
Number of subjects: 140
Study 24161288 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: MP after lidocaine with a tourniquet with arm up (venous gravity drainage)
Number of subjects: 140
Study 24161288 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: MP with a tourniquet with arm down
Number of subjects: 140
Study 24161288 — intervention group
Group type: COMPARATOR
Intervention: Group D: Control group received MP only (with no tourniquet)
Number of subjects: 140
Study 21804435 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxide-based system (CIBA Vision ClearCare)
Number of subjects: 30
Study 21804435 — intervention group
Group type: COMPARATOR
Intervention: System preserved with Polyquad and Aldox (Alcon OPTI-FREE RepleniSH)
Number of subjects: 30
Study 19698996 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg caffeine
Number of subjects: 98
Study 19698996 — intervention group
Group type: COMPARATOR
Intervention: Caffeine-free solution
Number of subjects: 98
Study 17259128 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of methotrexate and mifepristone
Number of subjects: 1706
Study 17259128 — intervention group
Group type: COMPARATOR
Intervention: Exclusive use of methotrexate
Number of subjects: 1706
Study 15388539 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear heading drill with 20 balls at 88.71 km/h (55 mph)
Number of subjects: 4
Study 15388539 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational heading drill with 20 balls at 88.71 km/h (55 mph)
Number of subjects: 4
Study 15388539 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated rotational heading drill
Number of subjects: 4
Study 15388539 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heading drill)
Number of subjects: 4
Study 10978039 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (2400 mg twice daily)
Number of subjects: 24
Study 10978039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8992436 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional multivitamin supplementation including 0.8 mg folic acid
Number of subjects: 5502
Study 8992436 — intervention group
Group type: COMPARATOR
Intervention: Placebo-like trace-element control group
Number of subjects: 5502
Study 1591140 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene
Number of subjects: 0
Study 1591140 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 0
Study 1591140 — intervention group
Group type: COMPARATOR
Intervention: Frusemide or Hydrochlorothiazide
Number of subjects: 0
Study 6375276 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide twice daily
Number of subjects: 50
Study 6375276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30836396 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump beating-heart surgery
Number of subjects: 736
Study 30836396 — intervention group
Group type: COMPARATOR
Intervention: On-pump beating-heart surgery
Number of subjects: 736
Study 28600473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir (n = 30)
Number of subjects: 167
Study 28600473 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod (n = 33)
Number of subjects: 167
Study 25890835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU hCG 6 days post TAI (D6)
Number of subjects: 406
Study 25890835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU hCG 4 days post TAI (D4)
Number of subjects: 406
Study 25890835 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 406
Study 25890835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU hCG 6 days post TAI (D6) during summer
Number of subjects: 406
Study 25890835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU hCG 4 days post TAI (D4) during summer
Number of subjects: 406
Study 25890835 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) during summer
Number of subjects: 406
Study 25890835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU hCG 6 days post TAI (D6) during winter
Number of subjects: 406
Study 25890835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU hCG 4 days post TAI (D4) during winter
Number of subjects: 406
Study 25890835 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) during winter
Number of subjects: 406
Study 25890835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU hCG 4 days post TAI (D4) in primiparous cows
Number of subjects: 406
Study 25890835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU hCG 6 days post TAI (D6) in primiparous cows
Number of subjects: 406
Study 25890835 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) in primiparous cows
Number of subjects: 406
Study 25890835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU hCG 6 days post TAI (D6) in multiparous cows
Number of subjects: 406
Study 25890835 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) in multiparous cows
Number of subjects: 406